NCT01923740

A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)

A Clinical Evaluation of Absorb™ BVS, the Bioresorbable Vascular Scaffold, in the Treatment of Subjects With de Novo Native Coronary Artery Lesions in Chinese Population

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 480 (actual)
• Sponsor: Abbott Medical Devices · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and efficacy of the Absorb BVS System compared to the XIENCE V Everolimus Eluting Coronary Stent System (EECSS) in the treatment of subjects with ischemic heart disease caused by up to two de novo native coronary artery lesions in separate epicardial vessels.

Conditions

• Coronary Artery Disease
• Coronary Artery Stenosis
• Coronary Disease
• Coronary Stenosis

Interventions

Type	Name	Description
DEVICE	XIENCE V EECSS	Subjects receiving XIENCE V
DEVICE	Absorb BVS System	Subjects receiving Absorb BVS System

Timeline

• Start date: 2013-07-01
• Primary completion: 2015-05-01
• Completion: 2019-03-07
• First posted: 2013-08-16
• Last updated: 2019-12-04
• Results posted: 2018-02-14

Locations

1 site across 1 country: United States